Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
about
Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Dalbavancin for the treatment of paediatric infectious diseases.Treatment of Staphylococcus aureus Infections.Subinhibitory Dalbavancin Attenuates Exotoxin Production from Methicillin-sensitive and Methicillin-resistant Staphylococcus aureus in vitro.Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
P2860
Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Dalbavancin: A Novel Lipoglyco ...... inst Gram-Positive Infections.
@ast
Dalbavancin: A Novel Lipoglyco ...... inst Gram-Positive Infections.
@en
type
label
Dalbavancin: A Novel Lipoglyco ...... inst Gram-Positive Infections.
@ast
Dalbavancin: A Novel Lipoglyco ...... inst Gram-Positive Infections.
@en
prefLabel
Dalbavancin: A Novel Lipoglyco ...... inst Gram-Positive Infections.
@ast
Dalbavancin: A Novel Lipoglyco ...... inst Gram-Positive Infections.
@en
P2860
P1476
Dalbavancin: A Novel Lipoglyco ...... inst Gram-Positive Infections.
@en
P2093
Karrine D Roberts
Michael J Rybak
P2860
P2888
P304
P356
10.1007/S40121-015-0077-7
P577
2015-09-04T00:00:00Z